Uzunoglu B, Selcuk Balci M, Kalyoncu M, Karabulut S, Metin Cakar N, Yildiz C
Pediatr Pulmonol. 2025; 60(3):e71037.
PMID: 40062574
PMC: 11892081.
DOI: 10.1002/ppul.71037.
Schiavon M, Cobelli C, Nair K, Klaus K, Toffolo G, Zhang L
J Cyst Fibros. 2024; 24(1):57-65.
PMID: 39516143
PMC: 11788023.
DOI: 10.1016/j.jcf.2024.10.005.
Bestas A, Unal E, Aktar Karakaya A, Beyazit N, Savas S, Sen V
Sisli Etfal Hastan Tıp Bul. 2024; 58(3):389-394.
PMID: 39411039
PMC: 11472201.
DOI: 10.14744/SEMB.2024.65983.
Scully K, Marks B, Putman M
Diabetologia. 2024; 67(10):2143-2153.
PMID: 38995399
DOI: 10.1007/s00125-024-06223-3.
Scully K, Brenner L, Martin K, Ruazol M, Sawicki G, Uluer A
Front Endocrinol (Lausanne). 2024; 15:1293709.
PMID: 38379863
PMC: 10876871.
DOI: 10.3389/fendo.2024.1293709.
Screening for Turner Syndrome-Associated Hyperglycemia: Evaluating Hemoglobin A1c and Fasting Blood Glucose.
Parra Villasmil M, Ryckman K, Norris A, Pinnaro C
Horm Res Paediatr. 2023; 97(4):374-382.
PMID: 37788658
PMC: 10987397.
DOI: 10.1159/000534371.
Effects of insulin therapy optimization with sensor augmented pumps on glycemic control and body composition in people with cystic fibrosis-related diabetes.
Grancini V, Alicandro G, Porcaro L, Zazzeron L, Gramegna A, Morlacchi L
Front Endocrinol (Lausanne). 2023; 14:1228153.
PMID: 37720540
PMC: 10501717.
DOI: 10.3389/fendo.2023.1228153.
Continuous Glucose Monitoring as an Additional Tool in Early Cystic Fibrosis-Related Diabetes Monitoring and in Evaluation of Short-Term Sitagliptin Response.
Sebastian-Valles F, Arranz Martin J, Giron R, Knott-Torcal C, Sampedro-Nunez M, Martin-Adan J
Biomedicines. 2023; 11(6).
PMID: 37371849
PMC: 10296576.
DOI: 10.3390/biomedicines11061754.
Distribution of OGTT-Related Variables in Patients with Cystic Fibrosis from Puberty to Adulthood: An Italian Multicenter Study.
Foppiani A, Ciciriello F, Bisogno A, Bricchi S, Colombo C, Alghisi F
J Pers Med. 2023; 13(3).
PMID: 36983651
PMC: 10056682.
DOI: 10.3390/jpm13030469.
ISPAD Clinical Practice Consensus Guidelines 2022: Management of cystic fibrosis-related diabetes in children and adolescents.
Ode K, Ballman M, Battezzati A, Brennan A, Chan C, Hameed S
Pediatr Diabetes. 2022; 23(8):1212-1228.
PMID: 36537525
PMC: 10108242.
DOI: 10.1111/pedi.13453.
Endocrine Complications of Cystic Fibrosis.
Kelly A, Marks B, Stalvey M
Clin Chest Med. 2022; 43(4):773-789.
PMID: 36344080
PMC: 10291706.
DOI: 10.1016/j.ccm.2022.06.013.
Positive impact of insulin treatment on clinical trend in cystic fibrosis patients: a retrospective study.
Giugno A, Leonardi S, Lo Presti D, Timpanaro T, Parisi G, Papale M
Acta Biomed. 2022; 93(5):e2022295.
PMID: 36300234
PMC: 9686163.
DOI: 10.23750/abm.v93i5.12896.
Comparison of continuous glucose monitoring to reference standard oral glucose tolerance test for the detection of dysglycemia in cystic Fibrosis: A systematic review.
Kumar S, Pallin M, Soldatos G, Teede H
J Clin Transl Endocrinol. 2022; 30:100305.
PMID: 36200022
PMC: 9529501.
DOI: 10.1016/j.jcte.2022.100305.
Oxidative stress and impaired insulin secretion in cystic fibrosis pig pancreas.
OMalley Y, Coleman M, Sun X, Lei J, Yao J, Pulliam C
Adv Redox Res. 2022; 5.
PMID: 35903252
PMC: 9328447.
DOI: 10.1016/j.arres.2022.100040.
Metabolic Profile and Pathological Alterations in the Muscle of Patients with Early-Stage Amyotrophic Lateral Sclerosis.
Lanznaster D, Bruno C, Bourgeais J, Emond P, Zemmoura I, Lefevre A
Biomedicines. 2022; 10(6).
PMID: 35740329
PMC: 9220134.
DOI: 10.3390/biomedicines10061307.
Increased sputum lactate during oral glucose tolerance test in cystic fibrosis.
Jensen P, Nielsen B, Kolpen M, Pressler T, Faurholt-Jepsen D, Mathiesen I
APMIS. 2022; 130(8):535-539.
PMID: 35635299
PMC: 9545947.
DOI: 10.1111/apm.13233.
Can continuous glucose monitoring predict cystic fibrosis-related diabetes and worse clinical outcome?.
Zorron M, Marson F, Morcillo A, Goncalves A, El Beck M, Ribeiro J
J Bras Pneumol. 2022; 48(2):e20210307.
PMID: 35475864
PMC: 9064635.
DOI: 10.36416/1806-3756/e20210307.
Clinical practice versus guidelines for the screening of cystic fibrosis-related diabetes: A French survey from the 47 centers.
Weiss L, Ronsin O, Reynaud Q, Abely M, Mely L, Burgel P
J Clin Transl Endocrinol. 2022; 28:100298.
PMID: 35433271
PMC: 9010626.
DOI: 10.1016/j.jcte.2022.100298.
Retinopathy and microalbuminuria are common microvascular complications in cystic fibrosis-related diabetes.
Kempegowda P, Sunsoa H, Chandan J, Quinn L, Amrelia P, Atta S
Ther Adv Endocrinol Metab. 2022; 11:2042018820966428.
PMID: 35154634
PMC: 8832295.
DOI: 10.1177/2042018820966428.
The Effect of Control IQ Hybrid Closed Loop Technology on Glycemic Control in Adolescents and Adults with Cystic Fibrosis-Related Diabetes.
Scully K, Palani G, Zheng H, Moheet A, Putman M
Diabetes Technol Ther. 2022; 24(6):446-452.
PMID: 35020476
PMC: 9208855.
DOI: 10.1089/dia.2021.0354.